Accurate, Affordable Early Cancer Detection
Epi One’s groundbreaking diagnostic testing platform seeks to make cancer less scary by detecting cancer early enough to cure and accurately enough to treat appropriately. The company is currently in pre-revenue.
This Reg CF offering is made available through StartEngine Primary LLC, a member of FINRA/SPIC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Reasons to Invest
Epi One is innovating early cancer detection & disease prognosis with our innovative DNA-based biomarker identification methods, which we believe can be faster & more accurate than anything available in the market today.
Epi One aims to tap into the vast opportunity sitting at a technological inflection point with the U.S. Cancer Diagnostics Market, anticipated to reach $70B by 2032, expanding by 8.4% annually from 2023–2032.1
Backed by $3.1M in early angel funding and led by renowned CEO Michael Marquardt and a prolific scientific team, we believe Epi One is equipped to make its mark at the forefront of cancer research.
Epi One’s Biomarker Breakthrough
Epi One is a pre-market company pioneering disruptive DNA-based technologies in biomarker identification. Our innovations aim to enable early cancer detection, post-diagnosis monitoring, and prognosis assessment, all via a simple diagnostic kit.
Driven by the personal loss of both his first wife and his mother to cancer, Epi One's CEO, Michael Marquardt, has worked diligently with elite scientists Dr. Sophia F. Fang and Dr. Neng Yang to solve this problem with the development of our highly accurate and rapid PCR-based test.
We plan for our PCR tests to be mass-producible, estimated to cost just $500 per patient. With an industry-leading 95% accuracy rate in tissue biopsy and a strong 70% accuracy in early patient blood samples from clinical validation work conducted over the last several years, we seek to make this test ubiquitous, providing highly accurate biomarkers initially for prostate cancer with plans to expand beyond into lung, pancreatic, and other cancers.
Challenges for Current Cancer Diagnosis
Invest on StartEngineMany cancers are treatable when caught early. Yet, traditional detection methods like MRIs, lab tests, and biopsies are costly, imprecise, and can take several days, weeks, or even months for results. This delay can lead to late diagnoses or even a misdiagnosis, ultimately reducing survival rates for those suffering from this disease.
- High False Positive Rate
- 20–40min
- Not available for some cancer types
- High False Positive & Negative Rate
- Days to Weeks
- Combined DNA, RNA, or protein biomarkers
- High False Negative for Some Cancer Types
- 2–10 Days
- Not Standardized
- Inaccuracy of Single Biomarker Leads to Complex Whole Genome Sequencing
- Takes Days
- Mostly Whole Genome Sequencing/Multi-omics Based LDT Test
Making Early Cancer Detection Accessible & Affordable
Combining cutting-edge high-throughput technology with our self-developed computational algorithms, Epi One has established a pipeline capable of identifying highly accurate biomarkers for both tumor-specific and multiple-cancer diagnosis, prognosis, and companion diagnosis.
Our innovative approach allows us to use fewer than 10 genes for diagnosis and prognosis, achieving over 95% accuracy for tissue tests and over 70% for early cancer blood tests using an easy PCR-based analysis.
We believe this industry-leading accuracy, coupled with the scalability and cost-effectiveness of our platform, can position us to be a potential leader in the current landscape of cancer diagnostics. Our business model focuses on initially providing laboratory-developed tests (LDTs) in CLIA Laboratories, with a second phase of FDA-approved diagnostic kits for mass distribution.
A Renaissance in Cancer Research
Epi One aims to revolutionize the U.S. cancer diagnostics market, anticipated to reach $70 billion by 2032, growing at a CAGR of 8.4% from 2023 to 2032.2 On a global scale, the cancer diagnostics market is expected to reach $258.54 billion by 2030, growing at the same 8.4% CAGR from 2022 to 2030.3
Having raised $3.1 million in two early angel rounds, we are backed by a stellar team led by CEO Michael Marquardt, the former Chair of the American Cancer Society's Board of Directors. More notably, our approach has garnered attention at industry events like the American Society of Clinical Oncology (ASCO) Annual Meeting, reflecting the excitement surrounding our work and the inflection point of cancer research as a whole.
- Novel and cancer specific
- < 10 biomarkers / tumor type
- 95% accuracy in tissue biopsy
- > 70% sensitivity for early stage blood test
- Six-hour turn around time
- Low cost efficiency
- Mass producible
- LDT Services
- Diagnostic Kit
Transforming Cancer Diagnoses
Using our breakthrough technology, Epi One has identified highly accurate molecular biomarkers followed by wet lab validation to greatly reduce the time and cost necessary for transitional cancer biomarker discovery—providing definitive solutions to longstanding challenges in cancer diagnosis.
By investing in Epi One, you're supporting a company seeking to revolutionize early cancer detection and care, with the potential to make a profound impact on millions of lives worldwide.
Invest in Epi One and our journey toward a future where cancer diagnosis is faster, more accurate, and more accessible than ever before.
Our Team
Learn More About Epi One
